RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Recent evidence suggests that imidazoline I-2 receptor ligands are suitable for combination therapy with opioids. Quantitative analysis of I-2 receptor ligands combined with non-opioid drugs is necessary for the justification of alternative pain therapies.
This study systematically examined the antihyperalgesic and response rate-suppressing effects of selective I-2 receptor ligands (2-BFI and phenyzoline) alone and in combination with acetaminophen.
Von Frey and Hargreaves tests were used to examine the antihyperalgesic effects of drugs in complete Freund's adjuvant (CFA)-induced inflammatory pain in rats. Food-reinforced schedule-controlled responding was used to assess the rate-suppressing effects of study drugs. Dose-addition and isobolographic analyses were used to assess drug-drug interactions for all assays.
2-BFI (3.2-17.8 mg/kg, i.p.), phenyzoline (17.8-100 mg/kg, i.p.), and acetaminophen (56-178 mg/kg, i.p.) all dose-dependently produced significant antinociceptive effects. When studied as combinations, 2-BFI and acetaminophen produced infra-additive to additive interactions while phenyzoline and acetaminophen produced additive to supra-additive interactions. The same drug combinations suppressed response rate in a supra-additive manner.
Quantitative analysis of the antihyperalgesic and response rate-suppressing effects suggests that I-2 receptor ligands are not well suited to combination therapy with acetaminophen.
